Skip to main content

Table 2 Main outcomes measures in control and intervention groups cluster level summaries

From: Effectiveness and safety of misoprostol distributed to antenatal women to prevent postpartum haemorrhage after child-births: a stepped-wedge cluster-randomized trial

Outcome

Control group (n=6)

Intervention group (n=6)

Risk differencec (Control-intervention) (95 % CI)

p-value

Primary outcome

 PPH Hb diffa ≥2g/dl (sd)

18.5 % (5.9)

11.4 % (8.4)

7.1 % (-3.1 % to 17.3 %)

0.14

 PPH Hb diffb ≥2g/dl (sd)

15.0 % (4.3)

11.1 % (3.0)

3.9 % (-1.5 % to 9.3 %)

0.12

Secondary outcomes

 Postpartum anaemia (sd)

43.3 % (10.0)

41.3 % (11.0)

2.0 % (-2.4 % to 6.4 %)

0.30

 Health facility births (sd)

87.5 % (7.3)

85.4 % (9.3)

2.1 % (-1.4 % to 5.6 %)

0.19

 Uterotonic use at birth (sd)

80.4 % (12.6)

91.4 % (7.0)

−11.0 % (-25.7 % to 3.6 %)

0.11

 Fever & shivering (sd)

14.9 % (3.4)

22.2 % (5.3)

−7.2 % (-11.1 % to -3.7 %)

0.005

  1. PPH postpartum haemorrhage, aHb diff=postpartum haemoglobin - antenatal haemoglobin in women followed within 3rd to 5th day; n=412 in control and n=377 in intervention, bHb difference in all women; n=1140 in control and n=909 in intervention, c risk difference at cluster level are in means, sd standard deviation, CI confidence interval